NCT07407465
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07407465
Title Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. (CHIMERA)
Acronym CHIMERA
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gruppo Oncologico del Nord-Ovest
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA | FRA | ESP | DEU


No variant requirements are available.